- Company
- Prolia's sales this year are ₩54.9 billion
- by Kim, Jin-Gu Dec 9, 2020 05:56am
- Amgen's osteoporosis treatment Prolia (Denosumab) is popular in the market after the expansion of benefits. Until the third quarter of this year, it was found that the cumulative sales amount increased by 87% compared to the same period last year. This is in contrast to the decline in sales of major osteoporosis treatments excluding Proli
- Company
- What drugs will their patents expire next year?
- by Kim, Jin-Gu Dec 9, 2020 05:56am
- 155 patents, including Hanmi's Amosartan, will expire next year. The patents of two NOACs (New Oral Anticoagulant), which have grown rapidly in recent years, are also set to expire next year. According to the MFDS on the 4th, there are a total of 155 patents scheduled to expire in 2021. Among these, the item that attracts the most attentio
- Company
- Dong-A ST’s Jublia is growing by 15%
- by Kim, Jin-Gu Dec 9, 2020 05:56am
- Jublia's sales in the market for athlete's foot treatment for nails increased significantly last summer. Sales of Fulcare, which was a leading item in the existing market, decreased by 30% compared to the previous year. It is observed to have decreased by half compared to 5 years ago. According to IQVIA, a drug market research agency on
- Company
- 117 Organon-transferring MSD employees files for a remedy
- by Dec 8, 2020 03:55pm
- 117 employees notified to transfer from MSD Korea to a new subsidiary Organon have requested a remedy for unfair transfer. Resisting against the transfer ordered without consent, the MSD Korea Labor Union filed a remedy for unfair transfer to the Seoul Regional Labor Relations Commission on Dec. 1. The application for the remedy was
- Company
- Emerging Chinese company BeiGene readies for Korean market
- by Eo, Yun-Ho Dec 8, 2020 06:12am
- A China-based emerging pharmaceutical company, BeiGene is readying for the South Korean market. The pharmaceutical industry sources reported the Chinese company has opened a South Korean subsidiary recently. The company has already recruited Head of Medical Affairs Kim Jiyoon, previously worked in medical affairs at Sanofi Genzyme, and t
- Company
- Coverage expansion this year 70% less than last year
- by Eo, Yun-Ho Dec 8, 2020 06:11am
- Apparently, the number of new drug reimbursement expansion has gone down significantly this year. Daily Pharm surveyed the pharmaceutical reimbursement status from 2019 to 2020 and found the number of reimbursement expansion dropped 70 percent and 75 percent by indication compared to last year. The statistic data includes reimbursement e
- Company
- Roche Xofluza to be prescribed for flu prevention in Korea
- by Eo, Yun-Ho Dec 8, 2020 06:11am
- The prescription of a next-generation influenza new drug Xofluza is to get accessible in South Korea for prevention purpose. According to the pharmaceutical industry sources, Roche Korea applied for approval on Xofluza to the Ministry of Food and Drug Safety (MFDS) after the drug’s new indication to prevent influenza was cleared by the
- Company
- Daewoong succeeded in evading patent for Belkyra
- by Kim, Jin-Gu Dec 7, 2020 06:06am
- Daewoong has passed the final gateway for the early release of a generic for Belkyra (Deoxycholic acid), an injection for improving submandibular fat. The original company Allergan succeeded in avoiding the remaining one of the two divisional patents. According to the pharmaceutical industry on the 3rd, the Intellectual Property Trial
- Company
- Ninlaro starts pricing negotiation after three long years
- by Eo, Yun-Ho Dec 4, 2020 05:55am
- An oral multiple myeloma treatment, Ninlaro is initiating the drug pricing negotiation to seek for the National Health Insurance (NHI) reimbursement. The pharmaceutical industry sources reported the drug has started the pricing negotiation with the National Health Insurance Service (NHIS) on the only oral option in multiple myeloma treat
- Company
- The liver cancer treatment market is fluctuating
- by Kim, Jin-Gu Dec 4, 2020 05:53am
- The liver cancer treatment market is fluctuating greatly. Sales of Nexavar (Sorafenib), which occupied an absolute position in the market, declined significantly, while sales of Lenvima (Lenvatinib) increased. Hanmi's Soranib, which succeeded in overcoming Nexavar's patent, is scheduled to be released, and attention is focused on whethe
